10.1007/s00125-021-05590-5 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, renal outcome, combination therapy, preceding drug, diabetic kidney disease Citation Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y and Kawanami D (2024) Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
Theyve made it into my daily routine, which is saying something because I dont just add anything
This is just a tiny glimpse of the data available to CivicScience clients
If you are receiving treatment for hormonal imbalances, your symptoms could subside, including irritability and reduced libido
